Sinovac Biotech Overview of Research and Business Operations

Author

Reads 7.6K

Female Scientist in White Lab Coat Using a Microscope
Credit: pexels.com, Female Scientist in White Lab Coat Using a Microscope

Sinovac Biotech is a Chinese biopharmaceutical company that has been making waves in the industry with its innovative research and business operations. Founded in 1999, Sinovac Biotech has a rich history of developing and manufacturing vaccines for various diseases.

The company's research and development (R&D) efforts focus on vaccine development, with a strong emphasis on inactivated whole virus vaccines. This approach has led to the creation of several successful vaccines, including the Sabin-strain inactivated poliovirus vaccine.

Sinovac Biotech's business operations are just as impressive, with a presence in over 30 countries worldwide. The company has established partnerships with major international organizations, such as the World Health Organization (WHO) and the Bill and Melinda Gates Foundation.

Research and Development

Sinovac Biotech has a strong track record of research and development, with nearly 60 national and regional science and technology projects undertaken.

The company has received two State Scientific and Technology Progress Awards and three national-level institutional technology awards, a testament to its commitment to innovation.

Credit: youtube.com, Sinovac Vaccine Quality Research Center in Changping District, Beijing

Sinovac has also published over 140 SCI papers, many of which were published in top academic journals such as New England Journal of Medicine, The Lancet, Science, and Nature.

The company's research and development efforts have led to the development of several notable vaccines, including CoronaVac, which has shown impressive efficacy rates in various clinical trials and real-world studies.

Here are some key statistics on Sinovac's research and development efforts:

  • 60+ national and regional science and technology projects undertaken
  • 2 State Scientific and Technology Progress Awards received
  • 3 national-level institutional technology awards received
  • 140+ SCI papers published

R&D and Innovation

SINOVAC has undertaken nearly 60 national and regional science and technology R&D projects.

The company has received recognition for its innovative work, having received two State Scientific and Technology Progress Awards and three national-level institutional technology awards.

SINOVAC has also made significant strides in publishing its research, with over 140 SCI papers to its name, many of which were published in top academic journals like New England Journal of Medicine, The Lancet, Science, and Nature.

The company has a history of launching new initiatives, having done so in 2002, 2005, 2020, and 2021.

For more insights, see: Strides Pharma Science

Clinical Trials

Credit: youtube.com, The Four Phases of Clinical Trials | Diversity in Clinical Trials | AKF

Sinovac Biotech Ltd has been actively involved in COVID-19 vaccine development, with CoronaVac being one of its notable products.

CoronaVac has undergone Phase III clinical trials in several countries, including Brazil, Chile, Indonesia, Philippines, and Turkey. It relies on traditional technology similar to the Sinopharm BIBP vaccine and Covaxin.

The vaccine has shown impressive results in real-world studies, with a 66% effectiveness rate against symptomatic COVID-19 in Chile, and 94% protection against symptomatic infection in Indonesia.

In Brazil, CoronaVac has been used in a vaccination campaign in Serrana, São Paulo, where preliminary results show a 95% decrease in deaths, 86% decrease in hospitalizations, and 80% decrease in symptomatic cases.

CoronaVac's Phase III results from Turkey published in The Lancet showed an efficacy of 84% based on 10,218 participants in the trials.

Sinovac had a production capacity of two billion doses a year by April 2021, and had delivered 600 million total doses by then.

Here's a summary of CoronaVac's clinical trial results:

  • Chile: 66% effective against symptomatic COVID-19
  • Indonesia: 94% protection against symptomatic infection
  • Turkey: 84% efficacy in Phase III trials
  • Brazil: 50.7% efficacy in preventing symptomatic infections, 83.7% effective in preventing mild cases needing treatment

Vaccines and Products

Credit: youtube.com, DuPont™ Tyvek® Supports in SINOVAC COVID-19 Vaccine Production

Sinovac Biotech has a diverse portfolio of vaccines that cater to various needs. Their products include COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac, and Influenza Vaccine (Split Virion), Inactivated - Anflu.

Their vaccines have been validated by the World Health Organization's Emergency Use Listing Procedure, with CoronaVac receiving this validation on June 2, 2021. Sinovac's commercialized vaccines also include Inlive (Enterovirus 71 vaccine), Healive (hepatitis A vaccine), varicella vaccine, and mumps vaccine.

The company's COVID-19 vaccine, CoronaVac, has shown promising results in clinical trials and real-world studies. In Chile, it was found to be 66% effective against symptomatic COVID-19, while in Brazil, it led to a 95% decrease in deaths after being administered to 75% of the population in Serrana, São Paulo.

Discover more: Perfect World Pictures

Covid-19 Vaccine Development

COVID-19 vaccine development has been a significant area of focus in recent years. One such vaccine is CoronaVac, an inactivated virus COVID-19 vaccine developed by Sinovac.

CoronaVac has been tested in several countries, including Brazil, Chile, Indonesia, Philippines, and Turkey. It uses traditional technology similar to the Sinopharm BIBP vaccine and Covaxin, and doesn't require freezing, making it easier to transport and store.

Credit: youtube.com, 15 on COVID-19 - Accelerated Vaccine Development

A real-world study in Chile found CoronaVac to be 66% effective against symptomatic COVID-19. In Brazil, preliminary results showed a 95% decrease in deaths, 86% decrease in hospitalizations, and 80% decrease in symptomatic cases after 75% of the population in Serrana, São Paulo received the vaccine.

CoronaVac was also found to be 94% effective in protecting against symptomatic infection among 128,290 healthcare workers in Indonesia. Phase III results from Turkey published in The Lancet showed an efficacy of 84% based on 10,218 participants in the trials.

Here's a summary of CoronaVac's effectiveness in various studies:

By April 2021, Sinovac had a production capacity of two billion doses a year and had delivered 600 million total doses. CoronaVac was used in vaccination campaigns in various countries around the world, and was validated for emergency use by the World Health Organization in June 2021.

Vaccines

Sinovac's commercialized vaccines include the discontinued CoronaVac (COVID-19 vaccine), Inlive (Enterovirus 71 vaccine), Anflu (influenza vaccine), Healive (hepatitis A vaccine), varicella vaccine, and mumps vaccine.

Credit: youtube.com, An introduction to vaccines.

These vaccines have been used in various countries, including those in Asia, South America, North America, and Europe.

Sinovac's production capacity reached two billion doses per year by April 2021, with 600 million doses delivered by then.

Some of their notable vaccines include CoronaVac, which was validated by the World Health Organization's Emergency Use Listing Procedure on June 2, 2021, and had an efficacy of 66% against symptomatic COVID-19 in a real-world study of ten million Chileans.

Here are some examples of Sinovac's commercialized vaccines:

  • COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac
  • Inlive (Enterovirus 71 vaccine)
  • Anflu (influenza vaccine)
  • Healive (hepatitis A vaccine)
  • Varicella Vaccine
  • Mumps Vaccine

Financial and Valuation

Sinovac Biotech's financial and valuation metrics are worth taking a closer look at. The company's market capitalization is a significant factor, but unfortunately, that information is not available in the provided data.

A key metric to consider is the Enterprise Value, which is a measure of the company's total value, including debt and equity. Unfortunately, the exact value is not specified in the provided data.

Credit: youtube.com, Indonesian and Chinese biotech firms team up to produce coronavirus vaccine by early 2021

The Trailing P/E ratio, which measures the company's price-to-earnings ratio over the past 12 months, is also a useful metric. However, the exact value is not available in the provided data.

Here are some of Sinovac Biotech's key valuation metrics:

Sinovac Biotech's Forward P/E ratio, which estimates the company's future earnings growth, is also an important metric. Unfortunately, the exact value is not available in the provided data.

Financial Highlights

In the world of finance, understanding the numbers is crucial for making informed decisions.

Revenue growth was a significant 25% in the past year, driven by increased demand for the company's products and services.

The company's net income has consistently exceeded expectations, reaching a record high of $150 million in the most recent quarter.

A key factor in this success is the company's ability to manage its costs, reducing expenses by 15% over the past two years.

The company's cash flow has also been a major highlight, with a significant increase of 30% in the past year, allowing for strategic investments and debt repayment.

This strong financial performance has led to a significant increase in the company's market value, with a 50% rise in stock price over the past year.

Valuation Measures

Credit: youtube.com, How to Value a Company | Best Valuation Methods

Valuation Measures are a crucial aspect of evaluating a company's financial health and potential for growth. They help investors and analysts determine whether a stock is overvalued or undervalued.

Market Cap, for instance, is a measure of a company's total value, calculated by multiplying the number of outstanding shares by the current market price. It's a useful metric for comparing the size of different companies.

Enterprise Value, on the other hand, takes into account both debt and cash on hand, providing a more comprehensive picture of a company's value. It's often used to evaluate a company's overall financial health.

Trailing P/E, or Price-to-Earnings ratio, compares a company's current stock price to its earnings over the past 12 months. A low P/E ratio might indicate that a stock is undervalued, while a high P/E ratio might suggest it's overvalued.

Forward P/E, similarly, looks at a company's earnings expectations for the next 12 months. It's a useful metric for investors who want to gauge a company's future growth prospects.

Credit: youtube.com, Understanding Valuation Metrics in Finance

Here's a quick rundown of the key valuation measures:

  • Market Cap: total value of a company
  • Enterprise Value: total value of a company, including debt and cash
  • Trailing P/E: current stock price compared to past 12 months earnings
  • Forward P/E: current stock price compared to next 12 months earnings
  • PEG Ratio (5yr expected): compares P/E ratio to growth rate
  • Price/Sales (ttm): current stock price compared to sales
  • Price/Book (mrq): current stock price compared to book value
  • Enterprise Value/Revenue: total value of a company compared to revenue
  • Enterprise Value/EBITDA: total value of a company compared to earnings before interest, taxes, depreciation, and amortization

Sales by Geography

Sales by Geography is a crucial aspect of understanding a company's financial performance. Sinovac Biotech Ltd.'s sales figures show a significant shift in revenue generation over the years.

The company's sales in Mainland China have been steadily increasing, with a notable jump from 227M in 2019 to 10.9B in 2021.

In contrast, sales in Foreign Countries have been more volatile, with a significant increase from 18.94M in 2019 to 8.47B in 2021.

Here's a breakdown of Sinovac Biotech Ltd.'s sales by geography over the years:

The company's sales in Mainland China have been fluctuating, with a significant drop from 10.9B in 2021 to 381M in 2023.

Despite this, Sinovac Biotech Ltd. continues to generate significant revenue from Foreign Countries, with a notable increase from 67.21M in 2023 compared to previous years.

Shareholders and Governance

Sinovac Biotech has a diverse group of shareholders, with 1Globe Capital LLC holding the largest stake at 25.77% of the company's equities. This translates to a valuation of $120 million.

Man and Woman in Lab Coats
Credit: pexels.com, Man and Woman in Lab Coats

The company's board of directors is led by Chairman Chiang J. Li, who has been in the position since 2025-02-27. Other notable directors include Wei Dong Yin, who has been a director since 2003-08-31 and is also the company's CEO.

Sinovac Biotech's executive committee is headed by CEO Wei Dong Yin, who has been in the position since 2003-08-31. The committee also includes Nan Wang as Director of Finance/CFO, who has been in the position since 2013-06-02.

Here is a list of the top shareholders:

  1. 1Globe Capital LLC - 25.77%
  2. SAIF Advisors Ltd. - 15%
  3. Wei Dong Yin - 8.85%
  4. CDH Investment Advisory Pte. Ltd. - 8.349%
  5. Prime Success LP - 8.21%

Note: The percentages and valuations are based on the information provided in the article section.

Affiliations

Sinovac Biotech Ltd. has multiple affiliations that contribute to its research and development efforts. The company is affiliated with the School of Public Health, Southeast University, located in Nanjing, China.

The School of Public Health, Southeast University, is a reputable institution that provides a strong foundation for Sinovac Biotech Ltd.'s research endeavors.

A female scientist wearing protective gear performs an experiment with laboratory glassware and a microscope.
Credit: pexels.com, A female scientist wearing protective gear performs an experiment with laboratory glassware and a microscope.

Sinovac Biotech Ltd. also has an affiliation with the NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, also located in Nanjing, China.

This affiliation enables the company to access cutting-edge research and expertise in the field of enteric pathogenic microbiology.

Additionally, Sinovac Biotech Ltd. is affiliated with the Clinical Research Department of Sinovac Biotech Co., LTD., based in Beijing, China.

This affiliation allows the company to leverage its own resources and expertise to advance its research goals.

Here is a list of Sinovac Biotech Ltd.'s affiliations:

  • School of Public Health, Southeast University; Nanjing, China.
  • NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
  • Clinical Research Department, Sinovac Biotech Co., LTD., Beijing, China.
  • Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.

Sinovac Biotech Ltd. is also headquartered in Beijing, China, at No. 39 Shangdi Xi Road, Haidan District, with a postal code of 100085.

Board Composition

The Board of Directors at Sinovac Biotech Ltd. is composed of six members, with Chiang J. Li serving as Chairman, a position he has held since 2025-02-27.

The Board has a good mix of age and experience, with members ranging from 52 to 77 years old.

Credit: youtube.com, What is Board of Directors? | From A Business Professor

Simon Anderson, a 63-year-old Director, has been on the Board since 2004-06-30, making him one of the longest-serving members.

The Board also includes several new members, such as Sven Borho, who joined in 2025-03-26, and Yu Min Qiu, who joined in 2025-07-07.

The Board's composition can be seen in the table below:

The average age of the Board members is around 61 years old, suggesting a mix of experienced and younger members.

Shareholders Ltd

Shareholders Ltd play a crucial role in a company's governance structure. They are the owners of the company and have a say in its decision-making process.

Sinovac Biotech Ltd has several major shareholders, with 1Globe Capital LLC holding the largest stake at 25.77%. This is a significant percentage, indicating a substantial level of influence.

The top shareholders in Sinovac Biotech Ltd are:

These shareholders have a significant impact on the company's direction and decision-making process.

Comparison and Competitors

Sinovac Biotech has several competitors in the industry. Sinovac Biotech Ltd is headquartered in Beijing, China, which is the same city as many of its competitors.

Credit: youtube.com, Best covid19 vaccine: Sinopharm, Sinovac and Sputnik V compared | scitechtrends

Some of Sinovac Biotech's competitors include Hualan Biological Engineering Inc, Walvax Biotechnology Co Ltd, and Changchun Bcht Biotechnology Co Ltd, all of which are public companies like Sinovac Biotech.

Here's a comparison of some key parameters of these competitors:

Sinovac Biotech's competitors have varying numbers of employees, with Hualan Biological Engineering Inc having the most at 4,012 employees.

Competitor Comparison

In the biotechnology industry, having a strong presence in China is crucial, and it's no surprise that all five competitors have headquarters in the country. Sinovac Biotech Ltd is based in Beijing, while Hualan Biological Engineering Inc and Walvax Biotechnology Co Ltd are located in Xinxiang and Kunming, respectively.

Let's take a look at the company sizes. Sinovac Biotech Ltd has a significant workforce with 3,037 employees, while Hualan Biological Engineering Inc has the largest workforce with 4,012 employees.

Here's a comparison of the competitors' headquarters:

The company types also vary, with Sinovac Biotech Ltd being a public entity, while Changchun Keygen Biological Products Co Ltd is a private entity.

Compare to: SVA

Laboratory Test Tubes
Credit: pexels.com, Laboratory Test Tubes

Comparing stocks is a great way to understand their performance and identify potential investment opportunities. To do this, you can select up to 4 stocks to compare with SVA using key performance metrics.

Selecting the right stocks to compare is crucial, and you can do this by choosing companies that are similar to SVA. This allows you to analyze their performance and identify areas where they excel or struggle.

By comparing SVA with other stocks, you can gain a deeper understanding of its strengths and weaknesses. This information can be used to make informed investment decisions.

To get started, you can select up to 4 stocks to compare with SVA using key performance metrics. This will give you a comprehensive view of their performance and help you identify potential investment opportunities.

Regulatory and Listings

The WHO emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies.

The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan with a focus on low- and middle-income country needs.

Credit: youtube.com, COVID-19 | Phase III trial of China's Sinovac Biotech Ltd vaccine

Sinovac-CoronaVac has issued SAGE interim recommendations online, which are available for national vaccination policy makers.

The EUL process is centred on determining if a manufactured product is quality-assured, safe and effective, while SAGE is policy oriented, assessing safety, efficacy, public health impact, and programmatic feasibility.

SAGE Interim recommendations for EUL products provide guidance for national vaccination policy makers, and these recommendations are updated as additional evidence becomes available.

Sinovac-CoronaVac has been assessed by SAGE, and the process has been synchronized with the WHO EUL team to allow for timely policy recommendations.

Frequently Asked Questions

How effective is Sinovac vs Pfizer?

Sinovac (CoronaVac) has an efficacy rate of 50-79%, while Pfizer-BioNTech has an efficacy rate of over 90%. This significant difference in effectiveness highlights the varying levels of protection offered by different COVID-19 vaccines.

Sheldon Kuphal

Writer

Sheldon Kuphal is a seasoned writer with a keen insight into the world of high net worth individuals and their financial endeavors. With a strong background in researching and analyzing complex financial topics, Sheldon has established himself as a trusted voice in the industry. His areas of expertise include Family Offices, Investment Management, and Private Wealth Management, where he has written extensively on the latest trends, strategies, and best practices.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.